A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy

Trial Profile

A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs Ozanimod (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms STEPSTONE
  • Sponsors Celgene Corporation; Receptos
  • Most Recent Events

    • 01 Nov 2017 Results presented at the 25th United European Gastroenterology Week
    • 17 Oct 2017 According to a Celgene Corporation mrdia release, data will be presented at the World Congress of Gastroenterology at ACG2017.
    • 16 Oct 2017 Results presented in a Celgene Corporation Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top